| | |

Managing Mesothelioma During the COVID-19 Pandemic: New Guidelines

Mesothelioma During the COVID-19 Pandemic

New guidance suggests that patients should continue to receive treatment for malignant mesothelioma during the COVID-19 pandemic. Two new reports include recommendations for hospitals to keep vulnerable patients safe.

COVID-19 is especially dangerous for people with lung-related cancers like pleural mesothelioma. Their immune systems are not as strong as healthy people and their lungs are already damaged. 

But two new reports suggests that it may be even riskier to put off treatment for lung cancers like mesothelioma during the COVID-19 pandemic. 

How the Virus Could Impact Lung Cancer Patients

Both of the new reports come from researchers in Pennsylvania. They focus on people with lung cancer rather than mesothelioma. But pleural mesothelioma is also a lung-related cancer. It carries many of the same risks and symptoms as lung cancer, making the guidelines relevant for mesothelioma during the COVID-19 pandemic, too. 

Even otherwise healthy people struggle to fight COVID-19. The reports say people with compromised immunity or poor lung function – such as mesothelioma patients – are even more vulnerable. Cancer treatment can make it even harder to fight off illness.

Patients undergoing treatment for mesothelioma during the COVID-19 pandemic may be tempted to delay therapy. They may see this as a way to avoid contracting the virus. But that could be a mistake. 

Managing Mesothelioma During the COVID-19 Pandemic Could be Different

The first article appears in JCO Oncology Practice. Researchers from the University of Pennsylvania write, “Although we have extensive treatment guidelines for the standard management of lung cancer…at this critical time, we may need to deviate from this standard of care as we try to balance the risk of COVID-19 and mortality from lung cancer.”

Among the suggestions could that could also apply to people with mesothelioma during the COVID-19 pandemic are:

  • Continue to follow standard treatment guidelines, where possible
  • Maximize physical distancing 
  • Streamline workflows to account for decreased staff
  • Use imaging techniques like PET or CT for staging
  • Use needle biopsy instead of putting instruments into the lungs
  • Minimize the number of radiotherapy visits by giving larger doses

The second report comes from doctors at Penn State Cancer Institute. They also advise minimizing face-to-face visits. They say patients should be screened for COVID-19 before having a surgery or chemotherapy. If they test positive, these treatments should be delayed. 

Just as importantly for patients managing mesothelioma during the COVID-19 pandemic, they say clinical trial enrollments should continue.

Malignant mesothelioma is a rare cancer with a poor prognosis. Clinical trials may offer the best chance of long-term mesothelioma survival.

Sources:

Singh, A, et al, “Management of Lung Cancer During the COVID-19 Pandemic”, July 2020, JCO Oncology Practice, https://ascopubs.org/doi/full/10.1200/OP.20.00286

Dingamans, AM, et al, “Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic”, July 1, 2020, Volume 15, Issue 7, Journal of Thoracic Oncology, https://www.jto.org/article/S1556-0864(20)30382-8/fulltext

Similar Posts

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Micro-RNAs May Offer New Way to Fight Mesothelioma

    Scientists at one of the world’s top mesothelioma research centers, the Asbestos Diseases Research institute in Sydney, Australia, say that restoring the expression of certain micro RNAs in the cells of mesothelioma patients may offer a new way to fight the disease. A microRNA is a small RNA molecule which is involved in the regulation of gene expression. According to a new report in the Annals of Oncology, the Australian scientists found reduced expression of the micro RNA-15 family (miR-15/16) in the cells of mice with mesothelioma. “When malignant pleural mesothelioma cell lines were compared with the normal mesothelial cell line MeT-5A, the downregulation of miR-15/16 was 2- to 10-fold,” they report. This finding is consistent with previous cancer research…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Treatment Uses Herpes Virus to Shrink Mesothelioma Tumors

    Researchers at a hospital in Sheffield, England are testing a potential new mesothelioma treatment based on the same virus that causes herpes. The small-scale trial is the first in the world to test the modified herpes simplex virus, HSV1716, in human mesothelioma patients. HSV1716 has been genetically engineered to infect and kill cancer cells without harming healthy cells. In laboratory studies on mesothelioma and some other cancers, it has been shown to be effective at shrinking tumors while causing limited toxicity. Just as significantly, HSV1716 increased survival rates among mice with various human cancers. The Phase I/II trial at Sheffield Experimental Cancer Medicine Centre is the next stage in development of HSV1716 as a viable mesothelioma treatment. The goal of…

  • | |

    New Mesothelioma Drug Kills Cancer Stem Cells

    Citing “significant enthusiasm within the mesothelioma community”, the manufacturers of a promising new mesothelioma drug say they have begun a major test of the drug in patients. Massachusetts-based Verastem, Inc. focuses on drugs that fight cancer by attacking the stem cells that give rise to them. Earlier this summer, the FDA granted orphan drug status to their stem cell inhibitor, defactinib, for the treatment of mesothelioma. The designation, which is reserved for drugs that fight the rarest of diseases, helps pave the way for testing and faster approval, depending on the results of clinical trials. “Development of a drug that preferentially kills cancer stem cells is a promising approach, as many standard-of-care treatments have been shown to either have no…